
This study evaluated zzso alone versus initial zzso followed by zzso in secondary prevention of zzso zzso events in adults with active zzso Cancer patients zzso zzso zzso with acute symptomatic zzso zzso events were randomly allocated to receive subcutaneous zzso zzso zzso every 12 hours for 5 days, followed by zzso zzso daily zzso zzso or zzso zzso daily zzso zzso for 175 days, or subcutaneous zzso zzso zzso every 12 hours for at least 5 days and until a stable international zzso ratio of 2 to 3 was achieved on oral zzso begun on day 2 and continued to day 180 zzso zzso There were no significant differences in major and minor bleeding rates between treatment zzso No bleeding events were zzso or zzso zzso treatment was zzso generally well zzso and effective for a zzso period in the secondary prevention of zzso zzso events in patients with active zzso 

